ABT Positive Sentiment Score: 75/100
Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2024. Third-quarter GAAP diluted EPS of $0.94 and adjusted ...
Wednesday, October 16, 2024 7 min read
Key Takeaway: Abbott reported its third-quarter results for 2024, revealing a GAAP diluted EPS of $0.94. The company's diversified business model demonstrated strength, with strong sales growth in the Medical Devices segment, particularly in diabetes care and structural heart products. However, challenges remained, as certain divisions like Nutrition experienced sales declines, and demand for COVID-19 testing continued to decrease. Abbott's management remains optimistic, raising the midpoint of its full-year EPS guidance range.
Full Press Release Details
ABBOTT PARK , Ill. , Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE: ABT ) today announced financial results for the third quarter ended Sept. 30, 2024 .
"Our results this quarter demonstrate the strength of our diversified business model," said Robert B. Ford , chairman and chief executive officer, Abbott. "We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year."
THIRD-QUARTER BUSINESS OVERVIEW Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect ® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
| Third Quarter 2024 Results (3Q24) |
| Sales 3Q24 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established Pharmaceuticals | | Medical Devices |
| U.S. | 4,202 | | 950 | | 1,032 | | — | | 2,216 |
| International | 6,433 | | 1,116 | | 1,380 | | 1,406 | | 2,531 |
| Total reported | 10,635 | | 2,066 | | 2,412 | | 1,406 | | 4,747 |
| % Change vs. 3Q23 | | | | | | | | | |
| U.S. | 10.1 | | 10.4 | | 1.8 | | n/a | | 14.2 |
| International | 1.7 | | (7.9) | | (3.8) | | 2.7 | | 9.6 |
| Total reported | 4.9 | | (0.3) | | (1.5) | | 2.7 | | 11.7 |
| Impact of foreign exchange | (2.5) | | (3.1) | | (2.9) | | (4.3) | | (1.6) |
| Impact of business exit* | (0.2) | | (0.6) | | — | | — | | — |
| Organic | 7.6 | | 3.4 | | 1.4 | | 7.0 | | 13.3 |
| Impact of COVID-19 testing sales (3) | (0.6) | | — | | (1.9) | | — | | — |
| Organic (excluding COVID-19 tests) | 8.2 | | 3.4 | | 3.3 | | 7.0 | | 13.3 |
| U.S. | 11.0 | | 11.9 | | 2.4 | | n/a | | 14.2 |
| International | 6.5 | | (2.6) | | 3.8 | | 7.0 | | 12.5 |
| First Nine Months 2024 Results (9M24) |
| Sales 9M24 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established Pharmaceuticals | | Medical Devices |
| U.S. | 11,982 | | 2,761 | | 2,775 | | — | | 6,435 |
| International | 18,994 | | 3,523 | | 4,046 | | 3,926 | | 7,499 |
| Total reported | 30,976 | | 6,284 | | 6,821 | | 3,926 | | 13,934 |
| % Change vs. 9M23 | | | | | | | | | |
| U.S. | 4.2 | | 8.1 | | (16.2) | | n/a | | 14.3 |
| International | 3.4 | | (1.1) | | (2.4) | | 2.1 | | 10.1 |
| Total reported | 3.7 | | 2.7 | | (8.5) | | 2.1 | | 12.0 |
| Impact of foreign exchange | (3.0) | | (3.1) | | (2.9) | | (7.3) | | (1.6) |
| Impact of business exit and acquisition* | 0.1 | | (0.4) | | — | | — | | 0.4 |
| Organic | 6.6 | | 6.2 | | (5.6) | | 9.4 | | 13.2 |
| Impact of COVID-19 testing sales (3) | (2.8) | | — | | (10.4) | | — | | — |
| Organic (excluding COVID-19 tests) | 9.4 | | 6.2 | | 4.8 | | 9.4 | | 13.2 |
| U.S. | 10.0 | | 9.0 | | 3.0 | | n/a | | 13.3 |
| International | 9.0 | | 4.2 | | 5.9 | | 9.4 | | 13.1 |
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
| Nutrition |
| Third Quarter 2024 Results (3Q24) |
| Sales 3Q24 ($ in millions) | Total | | Pediatric | | Adult |
| U.S. | 950 | | 568 | | 382 |
| International | 1,116 | | 387 | | 729 |
| Total reported | 2,066 | | 955 | | 1,111 |
| % Change vs. 3Q23 | | | | | |
| U.S. | 10.4 | | 12.2 | | 7.9 |
| International | (7.9) | | (21.6) | | 1.5 |
| Total reported | (0.3) | | (4.5) | | 3.6 |
| Impact of foreign exchange | (3.1) | | (1.8) | | (4.4) |
| Impact of business exit* | (0.6) | | — | | (1.1) |
| Organic | 3.4 | | (2.7) | | 9.1 |
| U.S. | 11.9 | | 12.2 | | 11.5 |
| International | (2.6) | | (18.0) | | 8.0 |
Worldwide Nutrition sales decreased 0.3 percent on a reported basis and increased 3.4 percent on an organic basis in the third quarter, led by growth in Adult Nutrition.
In Adult Nutrition, global sales increased 3.6 percent on a reported basis and 9.1 percent on an organic basis, which was led by growth of Ensure ® , Abbott's market-leading complete and balanced nutrition brand.
| First Nine Months 2024 Results (9M24) |
| Sales 9M24 ($ in millions) | Total | | Pediatric | | Adult |
| U.S. | 2,761 | | 1,646 | | 1,115 |
| International | 3,523 | | 1,377 | | 2,146 |
| Total reported | 6,284 | | 3,023 | | 3,261 |
| % Change vs. 9M23 | | | | | |
| U.S. | 8.1 | | 11.8 | | 3.2 |
| International | (1.1) | | (6.8) | | 2.8 |
| Total reported | 2.7 | | 2.5 | | 3.0 |
| Impact of foreign exchange | (3.1) | | (1.6) | | (4.4) |
| Impact of business exit* | (0.4) | | — | | (0.7) |
| Organic | 6.2 | | 4.1 | | 8.1 |
| U.S. | 9.0 | | 11.8 | | 5.0 |
| International | 4.2 | | (3.6) | | 9.7 |
| Diagnostics |
| Third Quarter 2024 Results (3Q24) |
| Sales 3Q24 ($ in millions) | Total | | Core Laboratory | | Molecular | | Point of Care | | Rapid Diagnostics |
| U.S. | 1,032 | | 332 | | 37 | | 103 | | 560 |
| International | 1,380 | | 982 | | 91 | | 43 | | 264 |
| Total reported | 2,412 | | 1,314 | | 128 | | 146 | | 824 |
| % Change vs. 3Q23 | | | | | | | | | |
| U.S. | 1.8 | | 4.5 | | (2.8) | | 6.0 | | (0.2) |
| International | (3.8) | | (1.5) | | (3.9) | | 0.7 | | (12.2) |
| Total reported | (1.5) | | — | | (3.6) | | 4.4 | | (4.4) |
| Impact of foreign exchange | (2.9) | | (4.3) | | (1.5) | | (0.2) | | (1.4) |
| Organic | 1.4 | | 4.3 | | (2.1) | | 4.6 | | (3.0) |
| Impact of COVID-19 testing sales (3) | (1.9) | | (0.2) | | (3.9) | | — | | (3.4) |
| Organic (excluding COVID-19 tests) | 3.3 | | 4.5 | | 1.8 | | 4.6 | | 0.4 |
| U.S. | 2.4 | | 4.8 | | 4.5 | | 6.0 | | (1.0) |
| International | 3.8 | | 4.4 | | 0.8 | | 1.3 | | 2.8 |
As expected, Diagnostics sales growth in the third quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales 3 . Worldwide COVID-19 testing sales were $265 million in the third quarter of 2024 compared to $305 million in the third quarter of the prior year.
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 3.3 percent on an organic basis.
Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales grew 0.1 percent on a reported basis and increased 4.5 percent on an organic basis, led by continued adoption of Abbott's Alinity ® family of diagnostics systems and testing portfolios.
| First Nine Months 2024 Results (9M24) |
| Sales 9M24 ($ in millions) | Total | | Core Laboratory | | Molecular | | Point of Care | | Rapid Diagnostics |
| U.S. | 2,775 | | 969 | | 112 | | 308 | | 1,386 |
| International | 4,046 | | 2,879 | | 272 | | 133 | | 762 |
| Total reported | 6,821 | | 3,848 | | 384 | | 441 | | 2,148 |
| % Change vs. 9M23 | | | | | | | | | |
| U.S. | (16.2) | | 5.6 | | (12.3) | | 6.6 | | (29.8) |
| International | (2.4) | | 0.3 | | (7.2) | | 4.8 | | (10.6) |
| Total reported | (8.5) | | 1.5 | | (8.7) | | 6.0 | | (24.0) |
| Impact of foreign exchange | (2.9) | | (4.8) | | (0.8) | | (0.1) | | (1.1) |
| Organic | (5.6) | | 6.3 | | (7.9) | | 6.1 | | (22.9) |
| Impact of COVID-19 testing sales (3) | (10.4) | | (0.2) | | (6.3) | | — | | (25.0) |
| Organic (excluding COVID-19 tests) | 4.8 | | 6.5 | | (1.6) | | 6.1 | | 2.1 |
| U.S. | 3.0 | | 5.9 | | (3.3) | | 6.6 | | (0.1) |
| International | 5.9 | | 6.7 | | (0.9) | | 5.1 | | 5.7 |
| Established Pharmaceuticals |
| Third Quarter 2024 Results (3Q24) |
| Sales 3Q24 ($ in millions) | Total | | Key Emerging Markets | | Other |
| U.S. | — | | — | | — |
| International | 1,406 | | 994 | | 412 |
| Total reported | 1,406 | | 994 | | 412 |
| % Change vs. 3Q23 | | | | | |
| U.S. | n/a | | n/a | | n/a |
| International | 2.7 | | 0.7 | | 8.1 |
| Total reported | 2.7 | | 0.7 | | 8.1 |
| Impact of foreign exchange | (4.3) | | (4.7) | | (3.1) |
| Organic | 7.0 | | 5.4 | | 11.2 |
| U.S. | n/a | | n/a | | n/a |
| International | 7.0 | | 5.4 | | 11.2 |
Established Pharmaceuticals sales increased 2.7 percent on a reported basis and 7.0 percent on an organic basis in the third quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 0.7 percent on a reported basis and increased 5.4 percent on an organic basis, led by growth in several geographies and therapeutic areas, including gastroenterology, cardiometabolic, and central nervous system/pain management.
| First Nine Months 2024 Results (9M24) |
| Sales 9M24 ($ in millions) | Total | | Key Emerging Markets | | Other |
| U.S. | — | | — | | — |
| International | 3,926 | | 2,910 | | 1,016 |
| Total reported | 3,926 | | 2,910 | | 1,016 |
| % Change vs. 9M23 | | | | | |
| U.S. | n/a | | n/a | | n/a |
| International | 2.1 | | 0.7 | | 6.4 |
| Total reported | 2.1 | | 0.7 | | 6.4 |
| Impact of foreign exchange | (7.3) | | (9.0) | | (2.2) |
| Organic | 9.4 | | 9.7 | | 8.6 |
| U.S. | n/a | | n/a | | n/a |
| International | 9.4 | | 9.7 | | 8.6 |
| Medical Devices |
| Third Quarter 2024 Results (3Q24) |
| Sales 3Q24 ($ in millions) | Total | | Rhythm Management | | Electro- physiology | | Heart Failure | | Vascular | | Structural Heart | | Neuro- modulation | | Diabetes Care |
| U.S. | 2,216 | | 288 | | 285 | | 252 | | 258 | | 270 | | 190 | | 673 |
| International | 2,531 | | 309 | | 325 | | 70 | | 441 | | 288 | | 46 | | 1,052 |
| Total reported | 4,747 | | 597 | | 610 | | 322 | | 699 | | 558 | | 236 | | 1,725 |
| % Change vs. 3Q23 | | | | | | | | | | | | | | | |
| U.S. | 14.2 | | 6.0 | | 15.8 | | 16.7 | | 2.8 | | 21.1 | | 0.8 | | 23.6 |
| International | 9.6 | | 5.7 | | 9.2 | | 5.2 | | 4.5 | | 9.2 | | 17.8 | | 13.3 |
| Total reported | 11.7 | | 5.9 | | 12.2 | | 14.0 | | 3.9 | | 14.6 | | 3.8 | | 17.1 |
| Impact of foreign exchange | (1.6) | | (1.1) | | (2.1) | | (0.4) | | (1.0) | | (1.9) | | (1.4) | | (2.0) |
| Organic | 13.3 | | 7.0 | | 14.3 | | 14.4 | | 4.9 | | 16.5 | | 5.2 | | 19.1 |
| U.S. | 14.2 | | 6.0 | | 15.8 | | 16.7 | | 2.8 | | 21.1 | | 0.8 | | 23.6 |
| International | 12.5 | | 7.9 | | 13.0 | | 6.6 | | 6.2 | | 12.6 | | 25.7 | | 16.5 |
Worldwide Medical Devices sales increased 11.7 percent on a reported basis and 13.3 percent on an organic basis in the third quarter, including double-digit organic growth in both the U.S. and internationally.
Sales growth was led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure, and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre ® , Navitor ® , TriClip ® , Amplatzer ® Amulet ® , and AVEIR ® .
In Electrophysiology, sales grew 12.2 percent on a reported basis and 14.3 percent on an organic basis, which included double-digit growth in catheters and cardiac mapping-related products.
In Diabetes Care, sales of continuous glucose monitors exceeded $1.6 billion and grew 19.1 percent on a reported basis and 20.7 percent on an organic basis.
| First Nine Months 2024 Results (9M24) |
| Sales 9M24 ($ in millions) | Total | | Rhythm Management | | Electro- physiology | | Heart Failure | | Vascular | | Structural Heart | | Neuro- modulation | | Diabetes Care |
| U.S. | 6,435 | | 851 | | 841 | | 733 | | 787 | | 761 | | 563 | | 1,899 |
| International | 7,499 | | 915 | | 983 | | 215 | | 1,325 | | 876 | | 142 | | 3,043 |
| Total reported | 13,934 | | 1,766 | | 1,824 | | 948 | | 2,112 | | 1,637 | | 705 | | 4,942 |
| % Change vs. 9M23 | | | | | | | | | | | | | | | |
| U.S. | 14.3 | | 6.4 | | 15.3 | | 11.0 | | 7.4 | | 16.7 | | 6.5 | | 24.3 |
| International | 10.1 | | 4.8 | | 12.6 | | 8.2 | | 4.2 | | 10.3 | | 16.5 | | 13.5 |
| Total reported | 12.0 | | 5.6 | | 13.8 | | 10.4 | | 5.4 | | 13.2 | | 8.4 | | 17.4 |
| Impact of foreign exchange | (1.6) | | (1.2) | | (2.6) | | (0.1) | | (1.3) | | (1.9) | | (1.5) | | (1.9) |
| Impact of acquisition* | 0.4 | | — | | — | | — | | 2.8 | | — | | — | | — |
| Organic | 13.2 | | 6.8 | | 16.4 | | 10.5 | | 3.9 | | 15.1 | | 9.9 | | 19.3 |
| U.S. | 13.3 | | 6.4 | | 15.3 | | 11.0 | | 0.1 | | 16.7 | | 6.5 | | 24.3 |
| International | 13.1 | | 7.1 | | 17.4 | | 8.9 | | 6.0 | | 13.7 | | 24.6 | | 16.5 |
ABBOTT'S EARNINGS-PER-SHARE GUIDANCE Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.34 to $3.40 . Abbott forecasts specified items for the full-year 2024 of $1.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.64 to $4.70 for the full-year 2024.
Abbott projects fourth-quarter 2024 diluted earnings per share under GAAP of $0.96 to $1.02 . Abbott forecasts specified items for the fourth-quarter 2024 of $0.35 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $1.31 to $1.37 for the fourth quarter 2024.
ABBOTT DECLARES 403 RD CONSECUTIVE QUARTERLY DIVIDEND On Sept. 19, 2024 , the board of directors of Abbott declared the company's quarterly dividend of $0.55 per share. Abbott's cash dividend is payable Nov. 15, 2024 , to shareholders of record at the close of business on Oct. 15, 2024 .
Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at
www.abbott.com and on LinkedIn , Facebook , Instagram , X and YouTube .
Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at
www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023 , and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
| 1 | In the third quarter of 2024, total worldwide sales were $10.635 billion and COVID-19 testing-related sales were $265 million. In the third quarter of 2023, total worldwide sales were $10.143 billion and COVID-19 testing-related sales were $305 million. |
| 2 | Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests. |
| 3 | Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below: |
| | Sales 3Q24 | | | COVID Tests Sales 3Q24 |
| ($ in millions) | U.S. | | Int'l | | Total | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 1,032 | | 1,380 | | 2,412 | | | 206 | | 59 | | 265 |
| Core Laboratory | 332 | | 982 | | 1,314 | | | 1 | | 2 | | 3 |
| Molecular | 37 | | 91 | | 128 | | | 2 | | 1 | | 3 |
| Rapid Diagnostics | 560 | | 264 | | 824 | | | 203 | | 56 | | 259 |
| | Sales 3Q23 | | | COVID Tests Sales 3Q23 |
| ($ in millions) | U.S. | | Int'l | | Total | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 1,013 | | 1,436 | | 2,449 | | | 207 | | 98 | | 305 |
| Core Laboratory | 317 | | 997 | | 1,314 | | | 2 | | 3 | | 5 |
| Molecular | 38 | | 95 | | 133 | | | 5 | | 3 | | 8 |
| Rapid Diagnostics | 561 | | 301 | | 862 | | | 200 | | 92 | | 292 |
| | Sales 9M24 | | | COVID Tests Sales 9M24 |
| ($ in millions) | U.S. | | Int'l | | Total | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 2,775 | | 4,046 | | 6,821 | | | 428 | | 143 | | 571 |
| Core Laboratory | 969 | | 2,879 | | 3,848 | | | 3 | | 5 | | 8 |
| Molecular | 112 | | 272 | | 384 | | | 7 | | 3 | | 10 |
| Rapid Diagnostics | 1,386 | | 762 | | 2,148 | | | 418 | | 135 | | 553 |
| | Sales 9M23 | | | COVID Tests Sales 9M23 |
| ($ in millions) | U.S. | | Int'l | | Total | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 3,309 | | 4,145 | | 7,454 | | | 1,031 | | 267 | | 1,298 |
| Core Laboratory | 917 | | 2,872 | | 3,789 | | | 6 | | 10 | | 16 |
| Molecular | 128 | | 293 | | 421 | | | 19 | | 17 | | 36 |
| Rapid Diagnostics | 1,975 | | 853 | | 2,828 | | | 1,006 | | 240 | | 1,246 |
| Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Third Quarter Ended September 30, 2024 and 2023 (in millions, except per share data) (unaudited) | |
| | 3Q24 | | 3Q23 | | % Change | |
| Net Sales | $10,635 | | $10,143 | | 4.9 | |
| Cost of products sold, excluding amortization expense | 4,698 | | 4,605 | | 2.0 | |
| Amortization of intangible assets | 470 | | 496 | | (5.1) | |
| Research and development | 713 | | 672 | | 6.1 | |
| Selling, general, and administrative | 2,895 | | 2,723 | | 6.3 | |
| Total Operating Cost and Expenses | 8,776 | | 8,496 | | 3.3 | |
| Operating Earnings | 1,859 | | 1,647 | | 12.8 | |
| Interest expense, net | 51 | | 69 | | (26.0) | |
| Net foreign exchange (gain) loss | (11) | | (10) | | n/m | |
| Other (income) expense, net | (121) | | (83) | | n/m | |
| Earnings before taxes | 1,940 | | 1,671 | | 16.1 | |
| Taxes on earnings | 294 | | 235 | | 25.6 | |
| Net Earnings | $1,646 | | $1,436 | | 14.6 | |
| Net Earnings excluding Specified Items, as described below | $2,119 | | $2,000 | | 5.9 | 1) |
| Diluted Earnings per Common Share | $0.94 | | $0.82 | | 14.6 | |
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $1.21 | | $1.14 | | 6.1 | 1) |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,748 | | 1,748 | | | |
| NOTES: |
| See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. |
| n/m = Percent change is not meaningful. |
| See footnotes on the following section. |
| 1) | 2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $473 million, or $0.27 per share, for intangible amortization, charges related to intangible impairment, expenses associated with acquisitions and a divestiture, and other net expenses. |
| | 2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $564 million, or $0.32 per share, for intangible amortization, charges related to the impairment of R&D intangible assets, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. |
| Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Nine Months Ended September 30, 2024 and 2023 (in millions, except per share data) (unaudited) | |
| | 9M24 | | 9M23 | | % Change | |
| Net Sales | $30,976 | | $29,868 | | 3.7 | |
| Cost of products sold, excluding amortization expense | 13,764 | | 13,419 | | 2.6 | |
| Amortization of intangible assets | 1,413 | | 1,485 | | (4.9) | |
| Research and development | 2,095 | | 2,041 | | 2.6 | |
| Selling, general, and administrative | 8,790 | | 8,225 | | 6.9 | |
| Total Operating Cost and Expenses | 26,062 | | 25,170 | | 3.5 | |
| Operating Earnings | 4,914 | | 4,698 | | 4.6 | |
| Interest expense, net | 170 | | 182 | | (6.4) | |
| Net foreign exchange (gain) loss | (17) | | 17 | | n/m | |
| Other (income) expense, net | (222) | | (370) | | n/m | |
| Earnings before taxes | 4,983 | | 4,869 | | 2.3 | |
| Taxes on earnings | 810 | | 740 | | 9.6 | 1) |
| Net Earnings | $4,173 | | $4,129 | | 1.0 | |
| Net Earnings excluding Specified Items, as described below | $5,851 | | $5,708 | | 2.5 | 2) |
| Diluted Earnings per Common Share | $2.38 | | $2.35 | | 1.3 | |
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $3.33 | | $3.25 | | 2.5 | 2) |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,749 | | 1,750 | | | |
| NOTES: |
| See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. |
| n/m = Percent change is not meaningful. |
| See footnotes on the following section. |
| 1) | 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
| | 2023 Taxes on Earnings includes the recognition of approximately $59 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
| 2) | 2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.678 billion, or $0.95 per share, for intangible amortization, charges related to intangible impairment, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. |
| | 2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.579 billion, or $0.90 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. |
| Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Third Quarter Ended September 30, 2024 and 2023 (in millions, except per share data) (unaudited) |
| | 3Q24 |
| | As Reported (GAAP) | | Specified Items | | As Adjusted |
| Intangible Amortization | $ 470 | | $ (470) | | $ — |
| Gross Margin | 5,467 | | 516 | | 5,983 |
| R&D | 713 | | (19) | | 694 |
| SG&A | 2,895 | | (5) | | 2,890 |
| Other (income) expense, net | (121) | | (12) | | (133) |
| Earnings before taxes | 1,940 | | 552 | | 2,492 |
| Taxes on Earnings | 294 | | 79 | | 373 |
| Net Earnings | 1,646 | | 473 | | 2,119 |
| Diluted Earnings per Share | $ 0.94 | | $ 0.27 | | $ 1.21 |
Specified items reflect intangible amortization expense of $470 million and other net expenses of $82 million associated with charges related to intangible impairment, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
| | 3Q23 |
| | As Reported (GAAP) | | Specified Items | | As Adjusted |
| Intangible Amortization | $ 496 | | $ (496) | | $ — |
| Gross Margin | 5,042 | | 542 | | 5,584 |
| R&D | 672 | | (46) | | 626 |
| SG&A | 2,723 | | (43) | | 2,680 |
| Other (income) expense, net | (83) | | (23) | | (106) |
| Earnings before taxes | 1,671 | | 654 | | 2,325 |
| Taxes on Earnings | 235 | | 90 | | 325 |
| Net Earnings | 1,436 | | 564 | | 2,000 |
| Diluted Earnings per Share | $ 0.82 | | $ 0.32 | | $ 1.14 |
Specified items reflect intangible amortization expense of $496 million and other net expenses of $158 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
| Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Nine Months Ended September 30, 2024 and 2023 (in millions, except per share data) (unaudited) |
| | 9M24 |
| | As Reported (GAAP) | | Specified Items | | As Adjusted |
| Intangible Amortization | $ 1,413 | | $ (1,413) | | $ — |
| Gross Margin | 15,799 | | 1,540 | | 17,339 |
| R&D | 2,095 | | (81) | | 2,014 |
| SG&A | 8,790 | | (96) | | 8,694 |
| Other (income) expense, net | (222) | | (183) | | (405) |
| Earnings before taxes | 4,983 | | 1,900 | | 6,883 |
| Taxes on Earnings | 810 | | 222 | | 1,032 |
| Net Earnings | 4,173 | | 1,678 | | 5,851 |
| Diluted Earnings per Share | $ 2.38 | | $ 0.95 | | $ 3.33 |
Specified items reflect intangible amortization expense of $1.413 billion and other net expenses of $487 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
| | 9M23 |
| | As Reported (GAAP) | | Specified Items | | As Adjusted |
| Intangible Amortization | $ 1,485 | | $ (1,485) | | $ — |
| Gross Margin | 14,964 | | 1,591 | | 16,555 |
| R&D | 2,041 | | (144) | | 1,897 |
| SG&A | 8,225 | | (67) | | 8,158 |
| Other (income) expense, net | (370) | | 34 | | (336) |
| Earnings before taxes | 4,869 | | 1,768 | | 6,637 |
| Taxes on Earnings | 740 | | 189 | | 929 |
| Net Earnings | 4,129 | | 1,579 | | 5,708 |
| Diluted Earnings per Share | $ 2.35 | | $ 0.90 | | $ 3.25 |
Specified items reflect intangible amortization expense of $1.485 billion and other net expenses of $283 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
A reconciliation of the third-quarter tax rates for 2024 and 2023 is shown below:
| | 3Q24 | |
| ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | |
| As reported (GAAP) | $ 1,940 | | $ 294 | | 15.2 % | |
| Specified items | 552 | | 79 | | | |
| Excluding specified items | $ 2,492 | | $ 373 | | 15.0 % | |
| | 3Q23 | |
| ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | |
| As reported (GAAP) | $ 1,671 | | $ 235 | | 14.0 % | |
| Specified items | 654 | | 90 | | | |
| Excluding specified items | $ 2,325 | | $ 325 | | 14.0 % | |
A reconciliation of the year-to-date tax rates for 2024 and 2023 is shown below:
| | 9M24 | |
| ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | |
| As reported (GAAP) | $ 4,983 | | $ 810 | | 16.3 % | 1) |
| Specified items | 1,900 | | 222 | | | |
| Excluding specified items | $ 6,883 | | $ 1,032 | | 15.0 % | |
| | 9M23 | |
| ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | |
| As reported (GAAP) | $ 4,869 | | $ 740 | | 15.2 % | 2) |
| Specified items | 1,768 | | 189 | | | |
| Excluding specified items | $ 6,637 | | $ 929 | | 14.0 % | |
| 1) | 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
| 2) | 2023 Taxes on Earnings includes the recognition of approximately $59 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
| Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation Third Quarter and Nine Months Ended September 30, 2024 and 2023 ($ in millions) (unaudited) |
| | | 3Q24 | | 3Q23 | | % Change vs. 3Q23 |
| | | | | | | | | | | | | Non-GAAP |
| | | Abbott Reported | Impact from business exit (b) | Adjusted Revenue | | Abbott Reported | Impact from business exit (b) | Adjusted Revenue | | Reported | | Adjusted | Organic |
| Total Company | | 10,635 | (5) | 10,630 | | 10,143 | (17) | 10,126 | | 4.9 | | 5.1 | 7.6 |
| U.S. | | 4,202 | (5) | 4,197 | | 3,817 | (17) | 3,800 | | 10.1 | | 10.4 | 10.4 |
| Intl | | 6,433 | — | 6,433 | | 6,326 | — | 6,326 | | 1.7 | | 1.7 | 5.8 |
| Total Nutrition | | 2,066 | (5) | 2,061 | | 2,073 | (17) | 2,056 | | (0.3) | | 0.3 | 3.4 |
| U.S. | | 950 | (5) | 945 | | 860 | (17) | 843 | | 10.4 | | 11.9 | 11.9 |
| Intl | | 1,116 | — | 1,116 | | 1,213 | — | 1,213 | | (7.9) | | (7.9) | (2.6) |
| Adult Nutrition | | 1,111 | (5) | 1,106 | | 1,072 | (17) | 1,055 | | 3.6 | | 4.7 | 9.1 |
| U.S. | | 382 | (5) | 377 | | 354 | (17) | 337 | | 7.9 | | 11.5 | 11.5 |
| Intl | | 729 | — | 729 | | 718 | — | 718 | | 1.5 | | 1.5 | 8.0 |
| Total Medical Devices | | 4,747 | — | 4,747 | | 4,249 | — | 4,249 | | 11.7 | | 11.7 | 13.3 |
| U.S. | | 2,216 | — | 2,216 | | 1,940 | — | 1,940 | | 14.2 | | 14.2 | 14.2 |
| Intl | | 2,531 | — | 2,531 | | 2,309 | — | 2,309 | | 9.6 | | 9.6 | 12.5 |
| Vascular | | 699 | — | 699 | | 672 | — | 672 | | 3.9 | | 3.9 | 4.9 |
| U.S. | | 258 | — | 258 | | 251 | — | 251 | | 2.8 | | 2.8 | 2.8 |
| Intl | | 441 | — | 441 | | 421 | — | 421 | | 4.5 | | 4.5 | 6.2 |
| | 9M24 | | 9M23 | | % Change vs. 9M23 |
| | | | | | | | | | | | Non-GAAP |
| | Abbott Reported | Impact of acquisition (a) | Impact from business exit (b) | Adjusted Revenue | | Abbott Reported | Impact from business exit (b) | Adjusted Revenue | | Reported | Adjusted | Organic |
| Total Company | 30,976 | (57) | (13) | 30,906 | | 29,868 | (32) | 29,836 | | 3.7 | 3.6 | 6.6 |
| U.S. | 11,982 | (53) | (13) | 11,916 | | 11,503 | (32) | 11,471 | | 4.2 | 3.9 | 3.9 |
| Intl | 18,994 | (4) | — | 18,990 | | 18,365 | — | 18,365 | | 3.4 | 3.4 | 8.3 |
| Total Nutrition | 6,284 | — | (13) | 6,271 | | 6,116 | (32) | 6,084 | | 2.7 | 3.1 | 6.2 |
| U.S. | 2,761 | — | (13) | 2,748 | | 2,553 | (32) | 2,521 | | 8.1 | 9.0 | 9.0 |
| Intl | 3,523 | — | — | 3,523 | | 3,563 | — | 3,563 | | (1.1) | (1.1) | 4.2 |
| Adult Nutrition | 3,261 | — | (13) | 3,248 | | 3,167 | (32) | 3,135 | | 3.0 | 3.7 | 8.1 |
| U.S. | 1,115 | — | (13) | 1,102 | | 1,081 | (32) | 1,049 | | 3.2 | 5.0 | 5.0 |
| Intl | 2,146 | — | — | 2,146 | | 2,086 | — | 2,086 | | 2.8 | 2.8 | 9.7 |
| Total Medical Devices | 13,934 | (57) | — | 13,877 | | 12,444 | — | 12,444 | | 12.0 | 11.6 | 13.2 |
| U.S. | 6,435 | (53) | — | 6,382 | | 5,631 | — | 5,631 | | 14.3 | 13.3 | 13.3 |
| Intl | 7,499 | (4) | — | 7,495 | | 6,813 | — | 6,813 | | 10.1 | 10.0 | 13.1 |
| Vascular | 2,112 | (57) | — | 2,055 | | 2,004 | — | 2,004 | | 5.4 | 2.6 | 3.9 |
| U.S. | 787 | (53) | — | 734 | | 733 | — | 733 | | 7.4 | 0.1 | 0.1 |
| Intl | 1,325 | (4) | — | 1,321 | | 1,271 | — | 1,271 | | 4.2 | 3.9 | 6.0 |
| (a) | Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024. |
| (b) | Reflects the impact of discontinuing the ZonePerfect ® product line in the Nutrition business. This action was initiated in March 2024. |
| Abbott Laboratories and Subsidiaries Details of Specified Items Third Quarter Ended September 30, 2024 (in millions, except per share data) (unaudited) |
| | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds |
| Gross Margin | $ — | | $ 2 | | $ 470 | | $ 44 | | $ 516 |
| R&D | — | | — | | — | | (19) | | (19) |
| SG&A | (7) | | 2 | | — | | — | | (5) |
| Other (income) expense, net | (5) | | — | | — | | (7) | | (12) |
| Earnings before taxes | $ 12 | | $ — | | $ 470 | | $ 70 | | 552 |
| Taxes on Earnings (d) | | | | | | | | | 79 |
| Net Earnings | | | | | | | | | $ 473 |
| Diluted Earnings per Share | | | | | | | | | $ 0.27 |
| The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
| a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. |
| b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
| c) | Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment and intangible asset impairment charges. |
| d) | Reflects the net tax benefit associated with the specified items. |
| Abbott Laboratories and Subsidiaries Details of Specified Items Third Quarter Ended September 30, 2023 (in millions, except per share data) (unaudited) |
| | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds |
| Gross Margin | $ 3 | | $ 19 | | $ 496 | | $ 24 | | $ 542 |
| R&D | (1) | | (13) | | — | | (32) | | (46) |
| SG&A | (22) | | (22) | | — | | 1 | | (43) |
| Other (income) expense, net | 5 | | — | | — | | (28) | | (23) |
| Earnings before taxes | $ 21 | | $ 54 | | $ 496 | | $ 83 | | 654 |
| Taxes on Earnings (d) | | | | | | | | | 90 |
| Net Earnings | | | | | | | | | $ 564 |
| Diluted Earnings per Share | | | | | | | | | $ 0.32 |
| The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
| a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as legal and other costs related to business acquisitions. |
| b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
| c) | Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments. |
| d) | Reflects the net tax benefit associated with the specified items. |
| Abbott Laboratories and Subsidiaries Details of Specified Items Nine Months Ended September 30, 2024 (in millions, except per share data) (unaudited) |
| | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds |
| Gross Margin | $ 2 | | $ 76 | | $ 1,413 | | $ 49 | | $ 1,540 |
| R&D | (4) | | (1) | | — | | (76) | | (81) |
| SG&A | (32) | | (17) | | — | | (47) | | (96) |
| Other (income) expense, net | (140) | | — | | — | | (43) | | (183) |
| Earnings before taxes | $ 178 | | $ 94 | | $ 1,413 | | $ 215 | | 1,900 |
| Taxes on Earnings (d) | | | | | | | | | 222 |
| Net Earnings | | | | | | | | | $ 1,678 |
| Diluted Earnings per Share | | | | | | | | | $ 0.95 |
| The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
| a) | Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
| b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
| c) | Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. |
| d) | Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
| Abbott Laboratories and Subsidiaries Details of Specified Items Nine Months Ended September 30, 2023 (in millions, except per share data) (unaudited) |
| | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds |
| Gross Margin | $ 15 | | $ 51 | | $ 1,485 | | $ 40 | | $ 1,591 |
| R&D | (13) | | (5) | | — | | (126) | | (144) |
| SG&A | (43) | | (28) | | — | | 4 | | (67) |
| Other (income) expense, net | 46 | | — | | — | | (12) | | 34 |
| Earnings before taxes | $ 25 | | $ 84 | | $ 1,485 | | $ 174 | | 1,768 |
| Taxes on Earnings (d) | | | | | | | | | 189 |
| Net Earnings | | | | | | | | | $ 1,579 |
| Diluted Earnings per Share | | | | | | | | | $ 0.90 |
| The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
| a) | Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. |
| b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
| c) | Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments. |
| d) | Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
21 %